 SunHerald.com |
Metastatic Soft-Tissue Or Bone Sarcomas, Oral Ridaforolimus Improved …
Medical News Today The SUCCEED trial using oral ridaforolimus met its primary endpoint of progression-free survival in patients with metastatic soft-tissue or bone sarcomas who had responded well to chemotherapy, Merck announced at the American Society of Clinical … Ariad-Merck Cancer Drug for Bones-Tissue Extends Patient Lives in Study Merck, ARIAD Present Ridaforolimus Data From SUCCEED Trial At ASCO – Update Ariad and Merck Say Sarcoma Drug Improves Survival |
View full post on Health – Google News
